Differential Impact of Antihypertensive Drugs on Cardiovascular Remodeling: a Review of Findings and Perspectives for HFpEF Prevention
Overview
Affiliations
Heart failure (HF) is an important health problem worldwide whose stages have traditionally been classified from A to D. In addition, HF can be categorized as that with preserved ejection fraction (HFpEF) and that with reduced ejection fraction (HFrEF). Hypertension and arterial stiffness in stage A HF are major drivers of the progression to left ventricular hypertrophy (LVH), a criterion of stage B HF. Although the pathogenesis of HFpEF is heterogeneous, affected patients tend to be older than HFrEF patients and have a greater prevalence of hypertension, which is closely associated with arterial stiffness and LVH. Thus, to treat HFpEF, the optimal intervention for improving prognosis is an aggressive approach to early-stage, i.e., Stage A and B, HF. This paper reviews the findings on arterial stiffness and LVH using conventional antihypertensive drugs such as angiotensin receptor II blockers (ARBs) and a new drug class for HF, ARB/neprilysin inhibitor (ARNi). Previous studies have suggested that the combination of an ARB with an L-T-type calcium channel blocker might be recommended for the improvement of arterial stiffness and regression of LVH. More recent research has shown that ARNi also improves central BP, which leads to a reduced afterload and a significant reduction in LVH. For optimal treatment of HFpEF, drug therapy should directly address arterial stiffness as well as hypertension.
Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K Hypertens Res. 2023; 47(1):6-32.
PMID: 37710033 DOI: 10.1038/s41440-023-01398-5.
Denervation or stimulation? Role of sympatho-vagal imbalance in HFpEF with hypertension.
Nagai M, Dote K, Forster C Hypertens Res. 2023; 46(7):1727-1737.
PMID: 37045971 DOI: 10.1038/s41440-023-01272-4.
Update on Hypertension Research in 2021.
Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M Hypertens Res. 2022; 45(8):1276-1297.
PMID: 35790879 PMC: 9255494. DOI: 10.1038/s41440-022-00967-4.
Seven-action approaches for the management of hypertension in Asia - The HOPE Asia network.
Kario K, Chia Y, Siddique S, Turana Y, Li Y, Chen C J Clin Hypertens (Greenwich). 2022; 24(3):213-223.
PMID: 35172037 PMC: 8925006. DOI: 10.1111/jch.14440.